Characterization of the metabolites of trans-resveratrol-3-O-glucoside in monkeys and dogs.

In this study, a liquid chromatography-tandem multi-stage mass spectrometry (LC/MSn) method was established to characterize the metabolites of TRG in monkeys and dogs. A total of seven metabolites of TRG besides the prototype were found, which were identified as TR (M1), TRN (M2), trans-resveratrol-4'-O-glucuronide (M2'), trans-resveratrol-3-O-glucoside-4'-O-glucuronide (M3), trans-resveratrol-3-O-glucoside-5-O-glucuronide (M3'), trans-resveratrol-3-sulfate (M4) and trans-resveratrol-4'-sulfate (M4'). Additionally, the metabolic pathways of TRG in monkeys and dogs were proposed. There were also species differences of metabolism of TRG between monkeys and dogs.

Soft and Hard Tissue Changes Following Immediate Placement or Immediate Restoration of Single-Tooth Implants in the Esthetic Zone: A Systematic Review and Meta-Analysis.

PURPOSE: This systematic review aimed to compare immediate protocols with conventional protocols of single-tooth implants in terms of changes in the surrounding hard and soft tissue in the esthetic area. MATERIALS AND METHODS: Electronic and manual searches were performed in PubMed, EMBASE, Cochrane, and other data systems for research articles published between January 2001 and December 2014. Only randomized controlled trials (RCTs) reporting on hard and or soft tissue characteristics following a single-tooth implant were included. Based on the protocol used in each study, the included studies were categorized into three groups to assess the relationships between the factors and related esthetic indexes. Variables such as marginal bone level changes (mesial, distal, and mean bone level), peri-implant soft tissue changes (papilla level, midbuccal mucosa, and probing depth), and other esthetic indices were taken into consideration. The data were analyzed using RevMan version 5.3, Stata 12, and GRADEpro 3.6.1 software. RESULTS: A total of 13 RCTs met the inclusion criteria. Four studies examined immediate implant placement, five studies examined immediate implant restoration, and four studies examined immediate loading. Comparing the bone level changes following immediate and conventional restoration, no significant differences were found in the bone level of the mesial site (standard mean difference [SMD] = -0.04 mm; 95% confidence interval [CI]: -0.25 to 0.17 mm), the distal site (SMD = -0.15 mm; 95% CI: -0.38 to 0.09 mm), and the mean bone level changes (SMD = 0.05 mm; 95% CI: -0.18 to 0.27 mm). The difference in the marginal bone level changes between immediate and conventional loading was also not statistically significant (SMD = -0.05 mm; 95% CI: -0.15 to 0.06 mm for the mesial site and SMD = -0.02 mm; 95% CI: -0.09 to 0.05 mm for the distal site). Soft tissue changes following immediate and conventional restoration reported no significant differences in the papillae level of the mesial site (SMD = 0.18 mm; 95% CI: -0.00 to 0.37 mm), the papillae level of the distal site (SMD = -0.12 mm; 95% CI: -0.34 to 0.09 mm), and the midbuccal mucosa (SMD = -0.22 mm; 95% CI: -1.29 to 0.85 mm). CONCLUSION: Within the limitations, it can be concluded that immediately placed, restored, or loaded single-tooth implants in the esthetic zone result in similar hard and soft tissue changes compared with conventional protocols.

An analysis of feasibility of bioethanol production from Taiwan sorghum liquor waste.

In order to evaluate the feasibility of using sorghum liquor waste for bioethanol production, we serially investigated the effectiveness of physical treatment, microwave irradiation pretreatment, enzymatic hydrolysis, and fermentation. Composition analysis revealed that Kinmen sorghum liquor waste (KS) and Chiayi sorghum liquor waste (CS) contain approximately 17.2+/-0.7% and 18.2+/-0.6% cellulose, 19.0+/-0.6% and 21.6+/-1.0% hemicellulose, 18.5+/-0.8% and 20.6+/-1.7% acid detergent lignin, and 22.1+/-0.7% and 23.3+/-0.4% starch, respectively, on dry weight basis. The reducing sugar yield obtained after microwave irradiation pretreatment and enzymatic hydrolysis of KS and CS were 331.1 and 341.3mg/g dry weight. The ethanol yields obtained after fermentation of KS and CS hydrolysates with Saccharomyces cerevisiae were 0.13 and 0.14 g/g dry weight, respectively. This operation of pretreatment may provide a suggestible pattern of utilizing feedstock that contain lignocellulose and starchy for ethanolic fermentation.

Pharmacokinetics of vertilmicin, a novel aminoglycoside antibiotic, in rats and dogs.

The pharmacokinetics of vertilmicin was investigated in rats and dogs following intramuscular or intravenous administration of vertilmicin. Following a single administration of an intramuscular dose, serum concentrations of vertilmicin peaked at 0.63 h in rats and 0.58 h in dogs. In rats, after intravenous administration of vertilmicin at dosages of 10, 20, and 40 mg/kg, the t1/2 values for vertilmicin were 0.81, 0.76, and 0.86 h, respectively, while after intramuscular administration of vertilmicin at dose of 20 mg/kg, the t1/2 value for vertiImicin was 0.79 h. In dogs, after intravenous or intramuscular administration of vertilmicin at a dose of 10 mg/kg, the t1/2 values for vertilmicin were 0.83 and 0.85 h, respectively. After intravenous dosing to rats vertilmicin was distributed to most organs and tissues, and kidney tissue exhibited the highest exposure, while the tissue with the lowest exposure was the brain. Following single intravenous administration of vertilmicin at a dose of 20 mg/kg to rats, about 81.1% of the vertilmicin was excreted in urine, while only 3.12 and 1.44% of the administered dose was excreted in feces and bile within 48 h. The mean values for the plasma protein binding of vertilmicin were 22.7 and 20.4% in rats and dogs, respectively. These results indicate that vertilmicin was rapidly absorbed and widely distributed into various tissues in rats. The pharmacokinetic behavior of vertilmicin was dose-dependent when increasing doses of vertilmicin were administered intravenously to rats. Renal excretion was the primary elimination route of vertilmicin following intravenous administration to rats.